Lloyd K G, Depoortere H, Scatton B, Schoemaker H, Zivkovic B, Manoury P, Langer S Z, Morselli P L, Bartholini G
Pharmacol Biochem Behav. 1985 Oct;23(4):645-52. doi: 10.1016/0091-3057(85)90432-0.
Four phenylpiperazine derivatives exhibited an activity similar to benzodiazepines and meprobamate in the 4-plate test. One of these (compound IV) demonstrated anxiolytic like activity in a step-down avoidance technique, in electroshock induced aggression and in the staircase test. In contrast to benzodiazepines, compound IV was not anticonvulsant, myorelaxant or sedative. Confirmation of the anxiolytic activity of compound IV in animal models was obtained in 3 separate clinical trials in anxious patients. The mechanism of action of these phenylpiperazines appears to be different from the benzodiazepines as they do not displace 3H-diazepam binding nor do they interact with other elements of the GABA receptor macromolecular complex. Instead, compound IV interacts with both dopaminergic and serotoninergic neuron systems. Thus, from this data it would appear that an activity at the benzodiazepine recognition site is not obligatory for anxiolytic activity in man or in animals models.
四种苯基哌嗪衍生物在四板试验中表现出与苯二氮䓬类和甲丙氨酯相似的活性。其中一种(化合物IV)在阶梯式回避试验、电休克诱发攻击试验和阶梯试验中表现出抗焦虑样活性。与苯二氮䓬类不同,化合物IV没有抗惊厥、肌松或镇静作用。在三项针对焦虑症患者的独立临床试验中,证实了化合物IV在动物模型中的抗焦虑活性。这些苯基哌嗪的作用机制似乎与苯二氮䓬类不同,因为它们既不取代3H-地西泮结合,也不与GABA受体大分子复合物的其他成分相互作用。相反,化合物IV与多巴胺能和5-羟色胺能神经元系统相互作用。因此,从这些数据来看,在人或动物模型中,在苯二氮䓬识别位点的活性对于抗焦虑活性似乎不是必需的。